%PDF-1.4
%
31 0 obj
<>
endobj
28 0 obj
<>
endobj
89 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-03-02T14:08:12Z
2024-03-28T17:02:42-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T17:02:42-07:00
application/pdf
Heather
2003-879.april
uuid:031665bf-1dd2-11b2-0a00-7008276d7200
uuid:031665c2-1dd2-11b2-0a00-b80000000000
endstream
endobj
17 0 obj
<>
endobj
18 0 obj
<>
endobj
32 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 7 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 9 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 11 0 R/Type/Page>>
endobj
99 0 obj
[103 0 R]
endobj
100 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.8 g
/T1_0 18 Tf
0.6114 0.7912 -0.7912 0.6114 35.383 35.2215 Tm
(Personal, non-commercial use only. The Journal of Rheumatology. Copyrigh\
t \251 2004. All rights reserved.)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
54 54 m
558 54 l
S
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2004; 31:4)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(794)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.1 396.47 -10.84 re
f*
0.5 w
109.25 59.1 396.47 -10.84 re
S
BT
0 0 0 1 k
/GS1 gs
/T1_2 1 Tf
-0.00011 Tc -0.0107 Tw 9.7 0 0 10 54 713.1616 Tm
(\(2000 mg/day; 20 patients\), infliximab \(5 mg/kg; 30 patients\),)Tj
0.0118 Tw 0 -1.2 TD
(and rituximab \(375 mg/m)Tj
0 Tc 0 Tw 6.3 0 0 6.5 153.748 704.4616 Tm
(2)Tj
-0.00011 Tc 9.7 0 0 10 159.4394 701.1616 Tm
(weekly )Tj
/T1_3 1 Tf
0 Tc 3.1492 0 Td
(\004)Tj
/T1_2 1 Tf
-0.00011 Tc 0.0118 Tw 0.8106 0 Td
[(4; 1)36.8 (1 patients\) combined)]TJ
0.0266 Tw -14.8298 -1.2 Td
[(with CS were ef)17.7 (fective in inducing remission in patients with)]TJ
0.0067 Tc 0.36819 Tw T*
[(active, and in some cases, refractory)64.8 (, )54.8 (ANCA-associated)]TJ
-0.00011 Tc -0.01379 Tw T*
(vasculitis. Further investigation of these agents in formal clin-)Tj
0.0966 Tw T*
[(ical trials appears justified. G. Hof)17.7 (fman also reported favor-)]TJ
0.0808 Tw T*
(able results with the use of anti-TNF agents \(etanercept in 7)Tj
0.20461 Tw T*
[(and infliximab in 1)36.8 (1\) in 15 patients with active, relapsing)]TJ
0.02499 Tw T*
[(T)69.9 (akayasu\325)54.8 (s arteritis.)]TJ
-0.0051 Tw 1.2371 -1.2 Td
(The workshop ended this year with a full-day postgraduate)Tj
0.1615 Tw -1.2371 -1.2 Td
[(review course on vasculitis or)17.7 (ganized in collaboration with)]TJ
0.0199 Tc 0.5952 Tw T*
[(the European League )54.9 (Against Rheumatism and the)]TJ
-0.00011 Tc 0.15289 Tw T*
[(International Society of Nephrology)64.8 (. )17.7 (The 12th International)]TJ
0.11839 Tw T*
[(V)110.8 (asculitis and )54.9 (ANCA)-295.7 (W)79.9 (orkshop will be held in Heidelber)17.7 (g,)]TJ
0 Tc 0.02499 Tw T*
[(Germany)64.9 (, June 1-4, 2005.)]TJ
/T1_4 1 Tf
-0.00011 Tc 8.3505 -2.4 Td
(SIMON CARETTE,)Tj
/T1_2 1 Tf
5.82 0 0 6 222.5152 521.1616 Tm
(MD, FRCPC, MPhil,)Tj
7.76 0 0 8 135 511.1616 Tm
(Professor of Medicine,)Tj
0 -1.25 TD
(Head, Rheumatology Division, )Tj
T*
(University Health Network/ Mount Sinai Hospital,)Tj
T*
[(T)69.9 (oronto, Canada. )]TJ
/T1_1 1 Tf
-10.4381 -2.5 Td
[(Addr)36.8 (ess r)36.8 (eprint r)36.8 (equest to Dr)110.7 (. S. Car)36.8 (ette, T)91.7 (or)36.8 (onto W)91.7 (estern Hospital, 399)]TJ
T*
[(Bathurst Str)36.8 (eet, FP)-257.3 (1-223, T)91.7 (or)36.8 (onto, ON M5T)-257.3 (2S8. E-mail:)]TJ
0 Tw T*
[(simon.car)36.8 (ette@uhn.on.ca)]TJ
/T1_4 1 Tf
9.7 0 0 10 318 713.1616 Tm
(REFERENCES)Tj
/T1_2 1 Tf
0.02499 Tw 8 0 0 8 325 703.1616 Tm
[(1.)-875.1 (Davies DJ, Moran JE, Niall JF)79.7 (, R)39.7 (yan GB. Segmental necrotising)]TJ
1.675 -1.25 Td
(glomerulonephritis with antineutrophil antibody: possible arbovirus)Tj
T*
(aetiology? BMJ 1982;285:606.)Tj
-1.675 -1.25 Td
[(2.)-875.1 (Falk RJ, Jennette CJ. )54.8 (Antineutrophil cytoplasmic antibodies with)]TJ
1.675 -1.25 Td
(specificity for myeloperoxidase in patients with systemic vasculitis)Tj
T*
(and idiopathic necrotizing and crescenteric glomerulonephritis. )Tj
0 Tc T*
(N Eng J Med 1988;318:1651-7.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(3.)-875.1 (Ludemann J, Utecht B, Gross )17.7 (WL. )54.8 (Antineutrophil cytoplasmic)]TJ
1.675 -1.25 Td
[(antibodies to )17.7 (W)79.9 (egener)-37 (\325)55.1 (s granulomatosis recognize an elastinolytic)]TJ
T*
(enzyme. J Exp Med 1990;171:357-62.)Tj
-1.675 -1.25 Td
[(4.)-875.1 (Xiao H, Heeringa P)110.7 (,)-0.1 ( Hu P)110.7 (, et al. )54.8 (Antineutrophil cytoplasmic)]TJ
1.675 -1.25 Td
(autoantibodies specific for myeloperoxidase cause glomeru-)Tj
T*
[(lonephritis and vasculitis in mice. J Clin Invest 2002;1)36.7 (10:955-63.)]TJ
-1.675 -1.25 Td
[(5.)-875.1 (Stegeman CA. )54.8 (Anti-neutrophil cytoplasmic antibody \(ANCA\))]TJ
1.675 -1.25 Td
(levels directed against proteinase-3 and myeloperoxidase are)Tj
T*
[(helpful in predicting disease relapse in )54.8 (ANCA-associated small-)]TJ
T*
[(vessel vasculitis. Nephrol Dial )17.7 (T)35 (ransplant 2002;17:2077-80.)]TJ
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_5 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_6 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
11 0 obj
<>stream
8;Z\6;%A:&%,:_6f^$0m)[o.L`2G>k#5s)#D.O%c`2=_P\-Xt$&4VMoo$f7WHU)qf
"&$9P0mDsKfMf`Y+cUGGI`b2dCZVu4E_//,3u+MU=2q>^$Z3$UF,CR4G*7`&,:[]8
Fd:K;k!JHD?54/D[C9$#/n^J0r\emDZ"5b]uM&\ZG*HXG2jcRq8rDPJ>%rp/k7I7\cfdL>D3sX[=87
hLN
+:*QA#iaBrIS:nF@%7s;hs@!]%_,Tl?fO'F1+2EM~>
endstream
endobj
15 0 obj
[/Indexed/DeviceRGB 255 14 0 R]
endobj
14 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
82 0 obj
<>
endobj
34 0 obj
<>
endobj
37 0 obj
<>
endobj
56 0 obj
<>
endobj
43 0 obj
<>
endobj
75 0 obj
<>
endobj
94 0 obj
<>
endobj
42 0 obj
<>
endobj
68 0 obj
<>stream
HLU{TW27eI}*E(eqUX
*URWiGZ{M9;s3~߽#!<=D2sV1uI&JI#z
qx 6xXf#T&*Vy2D~?ywl__);8-3srGhԫwR5z:̐hR\B&iZөc;1.1UkMu*'p[du`LݑQ-W'9V3}b&i8{[; 8Q1 J?l)1OJDI$V{q u#< D,"JHuo_IJ==JIԐ}hʔka:nlD?y+l# /fpf}\ŝ5Aͮ:]ͬò3ºtIs+ҭuA);W0|\Lr_\|9^rB9
f)g,/UK`I3@BrlO+sU8Ožx/ 0W9s
S5t6 b "i7H6EѮ(9P:n)+.,Z_w^\,@q\=un"Ăj y*j,sʋyaˌV,1 ߡ$53rڶpfrЋzAl#3f!](/jU/'W]ߐ
@ C7%˹w9p(0CC&Xpd<&^ie'"T0U"JP[y'K@+%vт}}+]\+)7+ּMyHʰڋT;\:A~)ό]F*+c>q,wTݡ
A KU@,n]mv\TK8HɠGha
Qfa댬FxL^_W""oPOiܞBoCeYe@a}4%
BTV `xāٰk l'~x6dA8f4HI8}뛣D~}[˨A O~Xb`|ՂF
bË|9t=a]Qhuf֮=̾u{ R}ר$рGن:'@HkAn;Цzpco<..
!"]完LiYWMSo)YpdG#MaQe^х'rS@25`k-YVd/?h.=Hohwe]V5މQh93t4$' VԾF*|+ZBs_d\jc0NUMyFs"SK~ypY\P|{PE("1
L{GAOmO8Ԟ]O-4LLfU/-?>SyQevE
cxL 90TU/軔w,K~*zt?/`)z}qX7k`Dc*q
xSwꎽ1/Njiaq\rgfjV91*2o /#|AL1m3ĨFs}p}u]{qϿ)Oãcs"lO*QtBe[^ Z[M-x_iMh ,.Oޫ9Ȅ#*摒sX.~XTYVwc?QH`74B 4(9UpKq:k